Vaxcyte
PCVX
55.39
-2.97
-5.09%
Vaxcyte
US · PCVX
#1630 by market cap
Listed 2020
55.39
-2.97
-5.09%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $125Market Newswire · 2026/10/20
-
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy RatingMarket Newswire · 2026/11/6
-
Rating change
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $116Market Newswire · 2026/7/14
-
Rating change
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Announces Target Price $133Market Newswire · 2026/8/6
-
Rating change
A Quick Look at Today's Ratings for Vaxcyte(PCVX.US), With a Forecast Between $122 to $163Market Newswire · 2026/10/6
-
Rating change
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110Market Newswire · 2026/9/25
-
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/11/5
-
Rating change
Cantor Fitzgerald Maintains Vaxcyte(PCVX.US) With Buy Rating, Announces Target Price $120Market Newswire · 2026/10/12
-
Rating change
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $75Market Newswire · 2026/2/25
-
Rating change
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $110Market Newswire · 2026/1/7
-
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $125Market Newswire · 2026/10/5
-
Rating change
Evercore Maintains Vaxcyte(PCVX.US) With Buy RatingMarket Newswire · 2026/5/21
-
Rating change
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $90Market Newswire · 2025/12/9
-
Rating change
Goldman Sachs Maintains Vaxcyte(PCVX.US) With Hold Rating, Raises Target Price to $85Market Newswire · 2026/10/7
-
BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $89Market Newswire · 2026/11/5
-
Rating change
Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $163Market Newswire · 2026/6/3
-
Rating change
Goldman Sachs Maintains Vaxcyte(PCVX.US) With Hold Rating, Maintains Target Price $67Market Newswire · 2026/2/26
-
Rating change
BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $85Market Newswire · 2026/2/13
-
Rating change
A Quick Look at Today's Ratings for Vaxcyte(PCVX.US), With a Forecast Between $67 to $133Market Newswire · 2026/2/26
-
Rating change
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2025/11/5
-
Rating change
BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $89Market Newswire · 2026/7/30
-
Rating change
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy RatingMarket Newswire · 2026/9/28
-
Rating change
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/8/6
-
Vaxcyte: Offerings Expected to Close Oct. 9 PCVXDow Jones · 2026/10/7
-
Rating change
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Cuts Target Price to $134Market Newswire · 2025/10/3
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Vaxcyte discussion 0 comments